About MIRA Pharmaceuticals Inc
- Industry: Pharmaceuticals
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://mirapharmaceuticals.com/
Frequently Asked Questions
What is the 52-week range for MIRA?
The 52-week high is $2.45 and the 52-week low is $0.6.
What is the P/E ratio for MIRA?
The P/E ratio data is currently unavailable.
What is the dividend yield for MIRA?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -140.83%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 6.08.
Analyst Recommendation Trends
Wall Street analyst consensus for MIRA over the last few months:
Latest MIRA News
Thursday's session: gap up and gap down stocks
The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Milestone Scientific (AMEX:MLSS) stock moved upwards by 11.8% to $0.44 during Monday's after-market session. The company's market cap stands at $36.9 million. Evotec (NASDAQ:EVO) stock rose 8.44% to
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) shares increased by 12.9% to $4.24 during Friday's after-market session. The market value of their outstanding shares is at $14.8 million. Geovax Labs (NASDAQ:GOVX) stock rose
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Protocol Submitted for IRB Review at a Leading Cancer Research Institution, Advancing the Study Toward Site InitiationMIAMI, Sept. 17, 2026 (GLOBE NEWSWIRE) -- MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and comments from the U.S. Food and Drug Administration (FDA), the Phase 2a protocol evaluating Ketamir-2 in chemotherapy-induced peripheral
Maxim Group Initiates Coverage On Mira Pharmaceuticals with Buy Rating, Announces Price Target of $3.5
Maxim Group analyst Jason McCarthy initiates coverage on Mira Pharmaceuticals (NASDAQ:MIRA) with a Buy rating and announces Price Target of $3.5.
MIRA Pharmaceuticals Submits Phase 2a Ketamir‑2 Protocol For CIPN To IRB, Incorporating FDA Feedback And Targeting Q1 2027 Site Initiation
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage pharmaceutical company developing novel oral small-molecule therapeutics, today announced that, following review and
Copper Giant Identifies Thirteen Targets Beyond the Mocoa Resource and Its Interpreted Extensions
Copper Giant Resources Corp. ("Copper Giant" or the "Company") (TSXV: CGNT) (OTCQX: CGNRF) (FRA: 29H0) today reports the results of an independent geophysical modelling and predictive targeting study completed by Mira Geoscience Ltd. ("Mira") over its Mocoa copper-molybdenum porphyry project in Putumayo, Colombia. The study covers an 81-square-kilometre area centered on the Mocoa deposit and defines 17 ranked target areas, 13 of them beyond the current resource footprint and its interpreted exte
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-06-12 | Whalen Matthew Pratt | +50,000 | - | - |
| 2026-06-12 | Shekhat Denil Nanji | +50,000 | - | - |
| 2026-06-12 | MacPherson Edward Clouston | +50,000 | - | - |
| 2026-06-12 | Del Giudice Matthew Paul | +50,000 | - | - |
| 2026-03-30 | Aminov Erez | +83,500 | - | - |
| 2025-12-17 | Aminov Erez | +3,155,170 | - | - |
| 2025-10-16 | Aminov Erez | +379,000 | - | - |
| 2025-10-16 | Aminov Erez | +234,595 | - | - |
| 2025-10-16 | Aminov Erez | -613,595 | $2.11 | $1,294,685 |
| 2025-10-16 | Aminov Erez | +379,000 | $0.84 | $318,360 |
| 2025-10-16 | Aminov Erez | +234,595 | $1.16 | $272,130 |